COM_RESEARCHSTUDIES_DETAIL_AVAL_STATUS_4

CD30 CAR-T cells for Hodgkin's/Non-Hodgkin's Lymphom

The purpose of this study is to establish a safe dose of study cells (ALTCAR.CD30) to give after chemotherapy and estimate progression free survival in pediatric patients with CD30+ refractory/relapsed Hodgkin lymphoma (HL) and non-Hodgkin lymphoma.

Age & Gender

3 years ~ 17 years
Male, Female, Gender Inclusive

Contact the Team

Location

COM_RESEARCHSTUDIES_DETAIL_HEADER_BASIC_CONTACT_4

North Carolina

Additional Study Information

Principal Investigator

Anne Beaven
Lineberger Comprehensive Cancer Center

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Lymphoma)

IRB Number

24-2127

ClinicalTrials.gov

NCT02690545

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.